Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
opakalim
- Development stage
- Phase 3
- Lead developer
- Biohaven
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Opakalim (BHV-7000) is a selective small molecule activator of the Kv7.2/Kv7.3 (KCNQ2/KCNQ3) potassium channels. Developed by Biohaven Pharmaceuticals, it is designed to stabilize neuronal membrane potential and reduce hyperexcitability, which is a key driver in seizure activity and mood disorders. The drug is currently in Phase 3 clinical development for focal epilepsy and idiopathic generalized epilepsy. While it was previously evaluated for major depressive disorder (MDD), a Phase 2 study failed to meet its primary endpoint, leading the company to focus its resources on epilepsy and other priority areas such as immunology and obesity.
- Other names
- opakalim
02
Targets
KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)
Beyond the preview
Go deeper on opakalim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on opakalim.